Economic Evaluations of Interventions to Optimize Medication Use in Older Adults with Polypharmacy and Multimorbidity: A Systematic Review

References

• Sirois C, Domingues NS, Laroche M-L, et al. Polypharmacy definitions for multimorbid older adults need stronger foundations to guide research, clinical practice and public health. Pharmacy. 2019;7(3):126. doi:10.3390/pharmacy7030126
   Web of Science ®Google Scholar
• Brown JD, Hutchison LC, Li C, Painter JT, Martin BC. Predictive validity of the beers and screening tool of older persons’ potentially inappropriate prescriptions (STOPP) criteria to detect adverse drug events, hospitalizations, and emergency department visits in the United States. J Am Geriatr Soc. 2016;64(1):22–30. doi:10.1111/jgs.1388426782849
   PubMed Web of Science ®Google Scholar
• Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360–372. doi:10.1111/jcpt.1205923550814
   PubMed Web of Science ®Google Scholar
• Kaufmann C, Tremp R, Hersberger K, Lampert M. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014;70(1):1–11. doi:10.1007/s00228-013-1575-824019054
   PubMed Web of Science ®Google Scholar
• van der Stelt C, Windsant-van den Tweel AV, Egberts A, et al. The association between potentially inappropriate prescribing and medication-related hospital admissions in older patients: a nested case control study. Drug Saf. 2016;39(1):79–87. doi:10.1007/s40264-015-0361-126553305
   PubMed Web of Science ®Google Scholar
• Black CD, Thavorn K, Coyle D, Bjerre LM. The health system costs of potentially inappropriate prescribing: a population-based, retrospective cohort study using linked health administrative databases in Ontario, Canada. PharmacoEconomics. 2020;4:27–36. doi:10.1007/s41669-019-0143-2
   Web of Science ®Google Scholar
• Santos NSD, Marengo LL, Moraes F da S, Barberato Filho S. Interventions to reduce the prescription of inappropriate medicines in older patients. Rev Saude Publica. 2019;53:7. doi:10.11606/S1518-8787.201905300078130726488
   PubMed Web of Science ®Google Scholar
• Hepler C, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–543.2316538
   PubMedGoogle Scholar
• Institute of Medicine (U.S.). Finding what works in health care standards for systematic reviews. National Academies Press; 2011. Available from: http://www.nap.edu/catalog.php?record_id=13059. Accessed 416, 2021.
   Google Scholar
• Le Reste JY, Nabbe P, Rivet C, et al. The European general practice research network presents the translations of its comprehensive definition of multimorbidity in family medicine in ten European languages. PLoS One. 2015;10(1):e0115796. doi:10.1371/journal.pone.011579625607642
   PubMed Web of Science ®Google Scholar
• Xu X, Mishra GD, Jones M. Evidence on multimorbidity from definition to intervention: an overview of systematic reviews. Ageing Res Rev. 2017;37(C):53–68. doi:10.1016/j.arr.2017.05.00328511964
   PubMed Web of Science ®Google Scholar
• Sorensen L, Stokes JA, Purdie DM, Woodward M, Elliott R, Roberts MS. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol. 2004;58(6):648–664. doi:10.1111/j.1365-2125.2004.02220.x15563363
   PubMed Web of Science ®Google Scholar
• O’Brien GL, O’Mahony D, Gillespie P, et al. Cost-effectiveness analysis of a physician-implemented medication screening tool in older hospitalised patients in Ireland. Drugs Aging. 2018;35(8):751–762. doi:10.1007/s40266-018-0564-030003429
   PubMed Web of Science ®Google Scholar
• Campins L, Serra-Prat M, Palomera E, Bolibar I, Martinez MA, Gallo P. Reduction of pharmaceutical expenditure by a drug appropriateness intervention in polymedicated elderly subjects in Catalonia (Spain). Gac Sanit. 2017;33(2):106–111. doi:10.1016/j.gaceta.2017.09.00229162290
   PubMed Web of Science ®Google Scholar
• Denneboom W, Dautzenberg MGH, Grol R, De Smet PAGM. Treatment reviews of older people on polypharmacy in primary care: cluster controlled trial comparing two approaches. Br J Gen Pract J R Coll Gen Pract. 2007;57(542):723–731.
   PubMed Web of Science ®Google Scholar
• Lin HW, Lin CH, Chang CK, et al. Economic outcomes of pharmacist-physician medication therapy management for polypharmacy elderly: a prospective, randomized, controlled trial. J Formos Med Assoc. 2018;117(3):235–243. doi:10.1016/j.jfma.2017.04.01728549592
   PubMed Web of Science ®Google Scholar
• Sirois C, Laroche M-L, Guénette L, Kröger E, Cooper D, Émond V. Polypharmacy in multimorbid older adults: protocol for a systematic review. Syst Rev. 2017;6(1). doi:10.1186/s13643-017-0492-9
   Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53–61. doi:10.18553/jmcp.2003.9.1.5314613362
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264. doi:10.7326/0003-4819-151-4-200908180-0013519622511
   PubMed Web of Science ®Google Scholar
• Gillespie P, Clyne B, Raymakers A, Fahey T, Hughes CM, Smith SM. Reducing potentially inappropriate prescribing for older people in primary care: cost-effectiveness of the Opti-script intervention. Int J Technol Assess Health Care. 2017;33(4):494–503. doi:10.1017/S026646231700078229019297
   PubMed Web of Science ®Google Scholar
• Patterson SM, Hughes CM, Cardwell C, Lapane KL, Murray AM, Crealey GE. A cluster randomized controlled trial of an adapted U.S. model of pharmaceutical care for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study): a cost-effectiveness analysis. J Am Geriatr Soc. 2011;59(4):586–593. doi:10.1111/j.1532-5415.2011.03354.x21453379
   PubMed Web of Science ®Google Scholar
• Twigg MJ, Wright D, Barton GR, Thornley T, Kerr C. The four or more medicines (FOMM) support service: results from an evaluation of a new community pharmacy service aimed at over-65s. Int J Pharm Pract. 2015;23(6):407–414. doi:10.1111/ijpp.1219625847545
   PubMedGoogle Scholar
• Malet-Larrea A, Goyenechea E, Gastelurrutia M, et al. Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients. Eur J Health Econ. 2017;18(9):1069–1078. doi:10.1007/s10198-016-0853-727913940
   PubMed Web of Science ®Google Scholar
• van der Heijden AA, de Bruijne MC, Nijpels G, Hugtenburg JG. Cost-effectiveness of a clinical medication review in vulnerable older patients at hospital discharge, a randomized controlled trial. Int J Clin Pharm. 2019;1–9. doi:10.1007/s11096-019-00825-330661216
   PubMed Web of Science ®Google Scholar
• Brixner D, Biltaji E, Bress A, et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016;19(3):213–228. doi:10.3111/13696998.2015.111016026478982
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford University Press; Accès via ProQuest Ebook Central - La consultation est limitée à un usager à la fois; 2015. Available from: https://ebookcentral.proquest.com/lib/ulaval/detail.action?docID=4605509. Accessed 416, 2021.
   Google Scholar
• Moriarty F, Cahir C, Bennett K, Fahey T. Economic impact of potentially inappropriate prescribing and related adverse events in older people: a cost-utility analysis using Markov models. BMJ Open. 2019;9(1):e021832. doi:10.1136/bmjopen-2018-021832
   PubMed Web of Science ®Google Scholar
• Silversides A. Pharmacies receiving massive rebates from generic drug-makers. CMAJ Can Med Assoc J. 2006;175(4):342. doi:10.1503/cmaj.06090416908889
   PubMed Web of Science ®Google Scholar
• Malet-Larrea A, Goyenechea E, Garcia-Cardenas V, et al. The impact of a medication review with follow-up service on hospital admissions in aged polypharmacy patients. Br J Clin Pharmacol. 2016;82(3):831–838. doi:10.1111/bcp.1301227195696
   PubMed Web of Science ®Google Scholar
• Parody Rúa E, Segu Tolosa JL. Efectividad y estimación de costes en una intervención sobre problemas relacionados con los medicamentos en atención primaria. Aten Primaria. 2005;35(9):472–477. doi:10.1157/1307547115919021
   PubMedGoogle Scholar
• Feletto E, Wilson LK, Roberts AS, Benrimoj S. Flexibility in community pharmacy: a qualitative study of business models and cognitive services. Pharm World Sci. 2010;32(2):130–138. doi:10.1007/s11096-009-9355-320016934
   PubMedGoogle Scholar
• Dolovich L, Gagnon A, McAiney CA, Sparrow L, Burns S. Initial pharmacist experience with the Ontario-based MedsCheck Program. Can Pharm J. 2008;141(6):339–345.e1. doi:10.3821/1913-701X-141.6.339
   Google Scholar
• Lynas K. Beyond bill 102: Ontario government reviews provincial drug system. Can Pharm J. 2009;142(5):212. doi:10.3821/1913-701X-142.5.212
   Google Scholar
• DeJong C, Aguilar T, Tseng C-W, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical industry–sponsored meals and physician prescribing patterns for medicare beneficiaries. JAMA Intern Med. 2016;176(8):1114–1122. doi:10.1001/jamainternmed.2016.276527322350
   PubMed Web of Science ®Google Scholar
• Fleischman W, Agrawal S, King M, et al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ. 2016;354:i4189. doi:10.1136/bmj.i418927540015
   PubMed Web of Science ®Google Scholar
• Trygstad TK, Christensen DB, Wegner SE, Sullivan R, Garmise JM. Analysis of the North Carolina long-term care polypharmacy initiative: a multiple-cohort approach using propensity-score matching for both evaluation and targeting. Clin Ther. 2009;31(9):2018–2037. doi:10.1016/j.clinthera.2009.09.00619843492
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed100009719621072
   PubMed Web of Science ®Google Scholar